Isolation rates for M kansasii appear to be stable in the UK, perhaps reflecting its environmental source. M kansasii has frequently been isolated from tap water and is thought to be acquired from the environment rather than from case to [2] [3] [4] [5] [6] case transmission.
Unlike Mycobacterium tuberculosis, M kansasii both infects and colonises the respiratory tract. Criteria for pulmonary infection include isolation (preferably multiple) with clinical and radiological findings compatible with mycobacterial disease.78 Infection with M kansasii has therapeutic implications as the organism shows in vitro resistance to pyrazinamide and often isoniazid. Drug regimens that include rifampicin and ethambutol are recommended8 9 and, when treated appropriately, outcome is good.'0"'3 However, the recent British Thoracic Society trial of treatment for nine months with rifampicin and ethambutol alone reported a relapse rate of 9% over a follow up period of five years. '3 It has been suggested previously that there are differences in the presentation ofpulmonary infection with non-tuberculous mycobacteria and M tuberculosis8' 4 but no systematic study has been published. Such differences, if present, would not only be of scientific interest, but would also be of potential clinical value. '5 Clinical suspicion ofM kansasii infection might allow ethambutol and rifampicin to be included in the initial drug regimen while awaiting culture results. Differentiating the two infections on clinical grounds might also have implications for contact tracing.
We Patients infected with M kansasii had a median of three sputum samples examined (range 1-9) and 29 (63%) had at least one smear positive result. Patients with M tuberculosis infection also had a median of three sputum samples examined (range 1-8) with 56 (64%) having at least one smear positive result. All M kansasii isolates were sensitive to rifampicin and ethambutol (one borderline sensitivity). Twelve were sensitive, 31 were of borderline sensitivity, and four were resistant to streptomycin. All were resistant to isoniazid and pyrazinamide resistance was assumed. All M tuberculosis isolates were sensitive to rifampicin, isoniazid, ethambutol, pyrazinamide (only 58 tested), and streptomycin (one borderline sensitivity).
There was no significant difference in the daily dosage of any antimycobacterial agent used in the treatment of M kansasii or M tuberculosis. The total duration of antimycobacterial chemotherapy was significantly longer forM kansasii (mean 10.3 months (range 0-22)) than for M tuberculosis (8.5 months (range 0-24); p =0.001). The most striking difference between the two groups was the prolonged use of ethambutol in the treatment of M kansasii (table 3) . No second line antimycobacterial drugs were used. We have shown that the clinical features of pulmonary M kansasii infection are generally similar to pulmonary M tuberculosis, but that differences do exist. Diabetes and heavy alcohol consumption appear to be rare in patients with M kansasii. The presence of these features, however, merely reinforces the already high prior likelihood of M tuberculosis, given that M tuberculosis was isolated eight times more frequently than M kansasii in the white population of Nottingham during the study period. Conversely, though haemoptysis and asthma were more common in the M kansasii group, the differences are not sufficiently great to have an impact on making a positive diagnosis of M kansasii. The relative isolation rates mentioned above mean that any particular patient with haemoptysis is still more likely to have M tuberculosis, and a patient with asthma has a similar risk of being infected with M tuberculosis or M kansasii. We have shown that it is not possible to differentiate reliably between pulmonary M kansasii infection and M tuberculosis infection on radiological grounds.'9 We now conclude that it is also not possible to predict the presence of pulmonary M kansasii infection on clinical grounds and that the group differences observed are unlikely to be clinically relevant.
All 47 isolates of M kansasii in our series came from patients of white race, most ofwhom were men (72%). The effect of race is difficult to interpret as only 8% of the population of Nottingham are from ethnic minorities, but the data suggest that M kansasii may be less common in the non-white population. Studies in the USA have also noted the predominance of white men in pulmonary M kansasii infection. 8 The reasons for this are unclear.
Haemoptysis has previously been noted to occur in 20-30% of patients with M kansasii infection'0 12 and the present study has confirmed haemoptysis as a common symptom (31 %), occurring more frequently than in pulmonary M tuberculosis infection. Possible reasons for this include the degree of endobronchial disease and the erosion of bronchial vessels by cavitation. While there are no data on the relative incidence of endobronchial disease, the incidence of cavitation is probably similar.'9 However, others have reported cavitation to be more common in pulmonary M kansasii infection than other pulmonary mycobacterial infections.20 Mycetomas, a potential confounding cause of haemoptysis, are probably less common in patients infected with M kan-sasii than with M tuberculosis and are uncommon on presentation."i92 22 data. Another possibility, however, is that more prolonged treatment, particularly of isoniazid (seven months in the present study compared with 2-4 months in the BTS study) led to a lower relapse rate. The fact that all M kansasii isolates displayed in vitro resistance to isoniazid does not discount the role of isoniazid as synergy between antimycobacterial drugs is well documented30 and discrepancy between in vitro sensitivity and treatment response is also recognised. 3' We conclude that differences between the clinical presentation of pulmonary M kansasii and M tuberculosis infections do exist but are unlikely to be clinically useful in the early identification of patients with pulmonary M kansasii infection. Our data support the prolonged use of ethambutol, rifampicin, and isoniazid for treatment of M kansasii infections.
The choice of this regimen at the earliest opportunity relies on good liaison with the laboratory. 
